Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed HR+ metastatic breast cancer, currently stable or minimally progressive on current endocrine-based therapy.~* Continuing on current endocrine-based therapy with an aromatase inhibitor, selective estrogen receptor degrader, or selective estrogen receptor modulator; and must be medically eligible to remain on this therapy during the treatment period.~Exclusion Criteria:~* Uncontrolled acute life-threatening bacterial, viral, or fungal infection.~* Subjects who are pregnant or breastfeeding~* Concurrent treatment with any cytotoxic chemotherapy agent or other targeted therapies including HER2 targeting therapies~* Currently receiving, or less than 28 days since ending treatment on another investigational drug.~* Clinically significant cardiovascular disease.~* Abnormal liver function.~* Any medical, psychiatric, or other condition which, in the opinion of the investigator, is likely to interfere with trial completion, assessments, or interpretation of trial results, or otherwise would make the subject an inappropriate subject for this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Ascending Dose followed by Multiple Doses (Type: EXPERIMENTAL): Up to 3 single ascending doses of GMI-1359 followed by the highest tolerated dose given for 3 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).